Overview of a chemoresponse assay in ovarian cancer

• Autores: J. V Fiorica, R. Holloway, D. Wang
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 9, 2014, págs. 761-769
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer. A total of sixty-seven articles, identified through PubMed using the key words �in vitro chemoresponse assay,� �chemo sensitivity resistance assay,� �ATP,� �HDRA,� �EDR,� �MiCK,� and �ChemoFx,� were reviewed. Recent publications on marker validation, including relevant clinical trial designs, were also included. Recent CSRA research and clinical studies are outlined in this review. Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs. Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer